Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $347.75 Consensus Price Target from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twenty-two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $347.75.

A number of research firms have weighed in on ALNY. HC Wainwright reissued a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Stifel Nicolaus lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a research note on Friday, July 11th. BMO Capital Markets lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday, June 24th. Finally, Jefferies Financial Group lifted their price objective on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. Commonwealth Equity Services LLC increased its stake in shares of Alnylam Pharmaceuticals by 23.3% during the 4th quarter. Commonwealth Equity Services LLC now owns 6,537 shares of the biopharmaceutical company's stock valued at $1,538,000 after acquiring an additional 1,234 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in shares of Alnylam Pharmaceuticals by 74.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,062 shares of the biopharmaceutical company's stock valued at $485,000 after acquiring an additional 880 shares during the last quarter. Quantbot Technologies LP increased its stake in shares of Alnylam Pharmaceuticals by 678.4% during the 4th quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company's stock valued at $374,000 after acquiring an additional 1,384 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after acquiring an additional 98,303 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 0.2%

NASDAQ:ALNY traded up $0.81 during mid-day trading on Thursday, hitting $328.81. The stock had a trading volume of 666,674 shares, compared to its average volume of 894,988. The stock has a 50-day simple moving average of $310.69 and a two-hundred day simple moving average of $274.03. The company has a market capitalization of $42.87 billion, a PE ratio of -157.33 and a beta of 0.23. Alnylam Pharmaceuticals has a twelve month low of $205.87 and a twelve month high of $333.70. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same period in the previous year, the business posted ($0.16) EPS. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.